PYRROLOPYRIMIDINE COMPOUNDS FOR MALIGNANT TUMOUR TREATMENT Russian patent published in 2017 - IPC C07D487/04 A61K31/519 A61P35/00 

FIELD: pharmacology.

SUBSTANCE: in formula I , one of X and X' is N, and the other X and X' is C; one of the dashed lines in formula I is a single bond, and the other dashed line in formula I is a double bond; R¹ is phenyl which may be substituted with 1 to 2 substituents selected from halogen atoms, S(O)₂R, where R is a 5-6-member cycloalkyl in which one CH₂ group is optionally replaced by an oxygen atom; NRaRb, -CH₂NRaRb, 1,1-cyclopropyl-NRaRb, S(O)₂NRaRb, wherein each Ra and Rb are hydrogen or both Ra and Rb are 4-6-member heterocycloalkyl which may further contain NH, N-CH₃, O (oxygen) as a heteroatom and may be substituted by halogen atoms; R² is -R⁵'R⁶, where R⁵' is a covalent bond or C₁-C₃alkyl, and R⁶ is C₆cycloalkyl, and wherein R⁶ is optionally substituted one to two times with independently selected polar groups selected from amino or hydroxy; R³ is -NR⁷R⁸, where one of R⁷ and R⁸ is selected from H, C₁-C₆alkyl, and the other R⁷ and R⁸ is selected from C₁-C₆alkyl, C₃-C₆thcycloalkyl-C₁-C₆alkyl, each of which is optionally substituted once with a polar group selected from hydroxy; or R² and R³ together form a linking group, wherein the linking group is -NH-(CH₂)₄-C(=O)-NH-(CH₂)₃-, R⁴ is H and R⁵ is H or a pharmaceutically acceptable salt thereof. The compounds are selected from IA or IB structure, where R¹-R⁵ have the values indicated in paragraph 1.

EFFECT: possibility to use for treatment of a malignant tumour selected from the group consisting of myeloid leukemia, lymphoblastic leukemia, melanoma, malignant breast, lung, colon, liver, stomach, kidney, ovary, uterus and brain.

14 cl, 3 tbl, 5 ex